Directory

Discover detailed profiles of PoC companies.

MEGALAB Co., Ltd.

Patented Microbiome Strains for Health, Beauty, and Functional Bio-Conversion Solutions

Specialization

Microbiome R&D
Patented Probiotic Strains
Multi-Strain Composition

Keywords

Microbiome
Patented Strains
Probiotics

MEGALAB is a microbiome company developing health functional foods, cosmetics, daily necessities, pet products, and bio-conversion solutions based on patented strains.
The company owns more than 1,000 commercially usable microbial resources selected from approximately 20,000 strains.
Its core technology is based on 13 patented microbiome strains and multi-strain composition technology for fermentation and bio-conversion.
MEGALAB provides microbiome-based product development, gut microbiota analysis, B2B solution consulting, and customized product advancement.

(1) Owned Technology

Patented probiotic strain development technology.
Bacillus subtilis P223-based microbiome complex technology.
Multi-strain composition technology for food, cosmetics, health supplements, and pet products.
MPC / MDS multi-strain bio-conversion technology.
Gut microbiota analysis and metagenomics-based evaluation platform.
AI predictive diagnostic device development based on intestinal microbiota big data.

(2) Applied Products

Patented Microbiome Strains
- 13 patented strains including Bacillus subtilis, Lactobacillus, Saccharomyces, Weissella, Leuconostoc, and Streptococcus strains.
Microbiome Health Functional Food
- Probiotic formulations for intestinal health, immunity, digestion, and wellness.
Microbiome Cosmetics
- Skin immunity, skin barrier, anti-inflammatory, antibacterial, and skin microbiome activation applications.
Gut Microbiota Analysis Service
- D2C intestinal microbiota analysis and reporting service.
B2B Bio-Conversion Solutions
- Customized fermentation and bio-conversion solutions for F&B, health functional food, animal feed, and cosmetics partners.

(1) Problem Definition / Development Background

Conventional commercial probiotic strains often have limited survival under gastric acid, bile acid, heat, and storage conditions.
Many probiotic products require high bacterial concentration because survival rate decreases before reaching the intestine.
Food, cosmetics, pet, and health supplement markets require functional strains with verified efficacy, stability, and field applicability.
B2B clients need customized microbiome solutions that can connect R&D, production, product development, and market data.

(2) Value Proposition / Solution

MEGALAB provides patented strains with high acid resistance, heat stability, shelf-life stability, and intestinal survivability.
The company’s Bacillus subtilis P223 shows antibacterial, anti-inflammatory, and antioxidant potential.
Multi-strain composition enables customized products for health, beauty, food, pet, and infant care markets.
MEGALAB connects R&D, clinical testing, product development, production, and market feedback into a continuous data-driven platform.

Patented Strain Portfolio: Owns 13 patented microbiome strains for fermentation, bio-conversion, and health applications.
High Survival Rate: MEGALAB strains showed 90% survival after 12 months, compared with lower rates in competitor samples.
Strong Acid Resistance: Strains can survive for more than 24 hours at pH 3–4 without capsules or coating.
Functional Efficacy: Bacillus subtilis P223 shows antibacterial, anti-inflammatory, and antioxidant activity.
Multi-Strain Synergy: 13-strain mix with Bacillus subtilis P223 showed strong antibacterial, anti-inflammatory, and antioxidant performance.
Clinical Data: Human IBS intake study over 14 days showed improvement in beneficial bacteria balance and reduction of harmful bacteria indicators.

Established in January 2018.
Business areas include microbiome-based health functional foods, cosmetics, and daily necessities.
Key partners include KT&G, Woongjin, Gemma Korea, PepsiCo, JungKwanJang, Sajo, Nature Republic, and research/medical institutions.
Conducts collaborative R&D with hospitals, clinics, universities, research institutes, and media organizations.
Runs product testing, clinical trials, microbiota analysis, and B2B microbiome consulting.
Conducted studies with medical institutions including Seoul National University Hospital, CHA Hospital, and Konkuk University Hospital.

(1) PoC Progress

MEGALAB has conducted R&D and B2B collaboration with partners in food, health functional food, animal feed, and cosmetics.
Bio-conversion partnership references include global and domestic partners such as PepsiCo, KT&G JungKwanJang, Sajo, and Nature Republic.
The company has accumulated clinical and field data through microbiome product usage, gut microbiota analysis, and B2B evaluations.

(2) Global Expansion

MEGALAB can expand its patented microbiome strain platform into global health functional food, cosmetics, pet care, and personalized healthcare markets.
Target customers include food and beverage companies, cosmetic brands, health supplement manufacturers, pet food companies, hospitals, clinics, and microbiome research partners.
The company aims to lead the microbiome market through patented strains, data-driven product advancement, and customized microbiome solutions.